| Title |
Spotlight on the relevance of mtDNA in cancer
|
|---|---|
| Published in |
Clinical and Translational Oncology, October 2016
|
| DOI | 10.1007/s12094-016-1561-6 |
| Pubmed ID | |
| Authors |
A. Cruz-Bermúdez, R. J. Vicente-Blanco, E. Gonzalez-Vioque, M. Provencio, M. Á. Fernández-Moreno, R. Garesse |
| Abstract |
The potential role of the mitochondrial genome has recently attracted interest because of its high mutation frequency in tumors. Different aspects of mtDNA make it relevant for cancer's biology, such as it encodes a limited but essential number of genes for OXPHOS biogenesis, it is particularly susceptible to mutations, and its copy number can vary. Moreover, most ROS in mitochondria are produced by the electron transport chain. These characteristics place the mtDNA in the center of multiple signaling pathways, known as mitochondrial retrograde signaling, which modifies numerous key processes in cancer. Cybrid studies support that mtDNA mutations are relevant and exert their effect through a modification of OXPHOS function and ROS production. However, there is still much controversy regarding the clinical relevance of mtDNA mutations. New studies should focus more on OXPHOS dysfunction associated with a specific mutational signature rather than the presence of mutations in the mtDNA. |
Mendeley readers
The data shown below were compiled from readership statistics for 54 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 54 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 13 | 24% |
| Student > Ph. D. Student | 9 | 17% |
| Student > Bachelor | 5 | 9% |
| Professor > Associate Professor | 5 | 9% |
| Student > Master | 5 | 9% |
| Other | 7 | 13% |
| Unknown | 10 | 19% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 21 | 39% |
| Agricultural and Biological Sciences | 9 | 17% |
| Medicine and Dentistry | 8 | 15% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 6% |
| Neuroscience | 1 | 2% |
| Other | 1 | 2% |
| Unknown | 11 | 20% |
Attention Score in Context
This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 October 2017.
All research outputs
#5,948,220
of 23,003,906 outputs
Outputs from Clinical and Translational Oncology
#245
of 1,319 outputs
Outputs of similar age
#90,407
of 314,437 outputs
Outputs of similar age from Clinical and Translational Oncology
#3
of 28 outputs
Altmetric has tracked 23,003,906 research outputs across all sources so far. This one has received more attention than most of these and is in the 73rd percentile.
So far Altmetric has tracked 1,319 research outputs from this source. They receive a mean Attention Score of 3.7. This one has done well, scoring higher than 81% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 314,437 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 70% of its contemporaries.
We're also able to compare this research output to 28 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 89% of its contemporaries.